Stevens Capital Management LP Increases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Stevens Capital Management LP grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 18.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,090 shares of the medical research company’s stock after acquiring an additional 2,311 shares during the quarter. Stevens Capital Management LP’s holdings in Edwards Lifesciences were worth $1,151,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Turtle Creek Wealth Advisors LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at approximately $34,000. Operose Advisors LLC raised its stake in Edwards Lifesciences by 247.0% during the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after buying an additional 452 shares during the last quarter. SRS Capital Advisors Inc. boosted its stake in shares of Edwards Lifesciences by 292.6% in the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after buying an additional 474 shares during the last quarter. NBC Securities Inc. bought a new stake in shares of Edwards Lifesciences in the third quarter worth $52,000. Finally, ORG Partners LLC purchased a new stake in Edwards Lifesciences during the third quarter valued at $66,000. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Heisz Leslie Stone sold 7,056 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $86.45, for a total transaction of $609,991.20. Following the transaction, the director now owns 26,980 shares of the company’s stock, valued at approximately $2,332,421. The disclosure for this sale can be found here. In the last quarter, insiders sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Trading Down 1.8 %

EW traded down $1.58 during trading hours on Friday, reaching $86.43. 4,979,943 shares of the company’s stock traded hands, compared to its average volume of 3,844,076. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $90.27 and a 200 day moving average price of $78.76. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The firm has a market capitalization of $52.02 billion, a PE ratio of 37.61, a PEG ratio of 4.39 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on EW shares. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday. Citigroup raised their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Mizuho lifted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Wells Fargo & Company raised their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Oppenheimer increased their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $93.33.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.